Sarcopenia and sarcopenic obesity in type 2 diabetes mellitus and cardiovascular disease: current perspective and narrative review.

Q3 Medicine
Endocrine regulations Pub Date : 2025-11-10 Print Date: 2025-01-01 DOI:10.2478/enr-2025-0023
Amanpreet Singh Wasir, Jagroop Singh Doad, Jasjeet Singh Wasir, Manish Bansal, Anuradha Rajiv Joshi
{"title":"Sarcopenia and sarcopenic obesity in type 2 diabetes mellitus and cardiovascular disease: current perspective and narrative review.","authors":"Amanpreet Singh Wasir, Jagroop Singh Doad, Jasjeet Singh Wasir, Manish Bansal, Anuradha Rajiv Joshi","doi":"10.2478/enr-2025-0023","DOIUrl":null,"url":null,"abstract":"<p><p>Sarcopenia, initially described as a disease of the elderly and its coexistence with obesity, now termed as 'sarcopenic obesity' (SO), are now emerging to be important health problems worldwide. Their relatively recent recognition as distinct clinical entities with growing research has shown an increasing prevalence of both sarcopenia and SO. There is a strong independent association, which exists between sarcopenia/SO, type 2 diabetes mellitus (T2DM), and cardiovascular disease (CVD). Studies investigating prevalence of sarcopenia/SO indicate considerable heterogeneity, likely due to the lack of a universally accepted definition, differences in age groups, gender, ethnicity, and socio-demographic factors of the population studied, apart from use of distinct diagnostic criteria and methods of estimation based on either muscle mass or strength.</p>","PeriodicalId":11650,"journal":{"name":"Endocrine regulations","volume":"59 1","pages":"199-205"},"PeriodicalIF":0.0000,"publicationDate":"2025-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Endocrine regulations","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2478/enr-2025-0023","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"Print","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Sarcopenia, initially described as a disease of the elderly and its coexistence with obesity, now termed as 'sarcopenic obesity' (SO), are now emerging to be important health problems worldwide. Their relatively recent recognition as distinct clinical entities with growing research has shown an increasing prevalence of both sarcopenia and SO. There is a strong independent association, which exists between sarcopenia/SO, type 2 diabetes mellitus (T2DM), and cardiovascular disease (CVD). Studies investigating prevalence of sarcopenia/SO indicate considerable heterogeneity, likely due to the lack of a universally accepted definition, differences in age groups, gender, ethnicity, and socio-demographic factors of the population studied, apart from use of distinct diagnostic criteria and methods of estimation based on either muscle mass or strength.

2型糖尿病和心血管疾病中的肌肉减少症和肌肉减少性肥胖:当前的观点和叙述综述。
肌肉减少症最初被描述为老年人的一种疾病,它与肥胖并存,现在被称为“肌肉减少性肥胖”(SO),现在正在成为世界范围内重要的健康问题。近年来,随着越来越多的研究表明,肌少症和SO的发病率不断上升,它们被视为独特的临床实体。肌少症/SO与2型糖尿病(T2DM)和心血管疾病(CVD)之间存在很强的独立关联。调查肌肉减少症/SO患病率的研究表明,除了使用不同的诊断标准和基于肌肉质量或力量的估计方法外,可能由于缺乏普遍接受的定义,年龄、性别、种族和研究人群的社会人口因素存在差异,存在相当大的异质性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Endocrine regulations
Endocrine regulations Medicine-Endocrinology, Diabetes and Metabolism
CiteScore
2.70
自引率
0.00%
发文量
33
审稿时长
8 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书